Literature DB >> 9517365

Antiretroviral therapy for patients with HIV disease.

M Barry1, F Mulcahy, D J Back.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9517365      PMCID： PMC1873374          DOI： 10.1046/j.1365-2125.1998.00673.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  49 in total

Review 1.  The HIV-1 protease as a therapeutic target for AIDS.

Authors:  C Debouck
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

2.  Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

Authors:  V A Johnson; D P Merrill; J A Videler; T C Chou; R E Byington; J J Eron; R T D'Aquila; M S Hirsch
Journal:  J Infect Dis       Date:  1991-10       Impact factor: 5.226

Review 3.  Current knowledge and future prospects for the use of HIV protease inhibitors.

Authors:  G Moyle; B Gazzard
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

4.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

Review 5.  CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review.

Authors:  D S Stein; J A Korvick; S H Vermund
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

6.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

7.  Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.

Authors:  A C Collier; R W Coombs; M A Fischl; P R Skolnik; D Northfelt; P Boutin; C J Hooper; L D Kaplan; P A Volberding; L G Davis; D R Henrard; S Weller; L Corey
Journal:  Ann Intern Med       Date:  1993-10-15       Impact factor: 25.391

8.  Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers.

Authors:  M Barry; M Wild; G Veal; D Back; A Breckenridge; R Fox; N Beeching; F Nye; P Carey; D Timmins
Journal:  AIDS       Date:  1994-08       Impact factor: 4.177

9.  HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.

Authors:  M J Kozal; R W Shafer; M A Winters; D A Katzenstein; E Aguiniga; J Halpern; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-08

10.  A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

Authors:  R Yarchoan; J A Lietzau; B Y Nguyen; O W Brawley; J M Pluda; M W Saville; K M Wyvill; S M Steinberg; R Agbaria; H Mitsuya
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226
View more
  2 in total

Review 1.  Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Authors:  M Barry; F Mulcahy; C Merry; S Gibbons; D Back
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

Review 2.  Forty Years Since the Epidemic: Modern Paradigms in HIV Diagnosis and Treatment.

Authors:  Karan Patel; Alex Zhang; Michelle H Zhang; Sean Bunachita; Basil M Baccouche; Henna Hundal; Liseth K Lavado; Aakshi Agarwal; Preeti Malik; Urvish K Patel
Journal:  Cureus       Date:  2021-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.